![]() |
|
|
Vol. 8, Issue 11, 2133-2143, November 1997
Receptors
Thoracic Research Unit and Department of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, Minnesota 55905
Submitted April 15, 1997; Accepted August 7, 1997| |
ABSTRACT |
|---|
|
|
|---|
Transforming growth factor
(TGF
) family ligands initiate a
cascade of events capable of modulating cellular growth and differentiation. The receptors responsible for transducing these cellular signals are referred to as the type I and type II TGF
receptors. Ligand binding to the type II receptor results in the transphosphorylation and activation of the type I receptor. This heteromeric complex then propagates the signal(s) to downstream effectors. There is presently little data concerning the fate of TGF
receptors after ligand binding, with conflicting reports indicating no
change or decreasing cell surface receptor numbers. To address the fate
of ligand-activated receptors, we have used our previously
characterized chimeric receptors consisting of the ligand binding
domain from the granulocyte/macrophage colony-stimulating factor
or
receptor fused to the transmembrane and cytoplasmic domain of the
type I or type II TGF
receptor. This system not only provides the
necessary sensitivity and specificity to address these types of
questions but also permits the differentiation of endocytic responses
to either homomeric or heteromeric intracellular TGF
receptor
oligomerization. Data are presented that show, within minutes of ligand
binding, chimeric TGF
receptors are internalized. However, although
all the chimeric receptor combinations show similar internalization
rates, receptor down-regulation occurs only after activation of
heteromeric TGF
receptors. These results indicate that effective
receptor down-regulation requires cross-talk between the type I and
type II TGF
receptors and that TGF
receptor heteromers and
homomers show distinct trafficking behavior.
| |
INTRODUCTION |
|---|
|
|
|---|
The transforming growth factor
(TGF
) superfamily of
polypeptides are involved in many processes regulating cellular growth and development (Massagué et al., 1990
). These
proteins bind to a novel superfamily of single-pass transmembrane
serine/threonine kinase receptors (Massagué et al.,
1992
; Kingsley 1994
; ten Dijke et al., 1994
). Nearly all
mammalian cells express three TGF
receptor species referred to as
the type I, type II, and type III receptor (Massagué et
al., 1990
). Recently, the receptor interactions necessary for
TGF
signaling have been defined (Wrana et al., 1994
;
Anders and Leof, 1996
; Luo and Lodish, 1996
). The type II receptor is a
constitutively active kinase capable of binding free ligand and
recruiting the type I receptor into an oligoheteromeric (di- and/or
tetramers) complex (Wrana et al., 1992
, 1994
; Yamashita et al., 1994
; Anders and Leof, 1996
; Luo and Lodish, 1996
;
Weis-Garcia and Massagué, 1996
). Phosphorylation of the type I
receptor by the type II initiates a signaling cascade(s) to downstream
effectors of which the Smad family of proteins may play a fundamental
role (Lagna et al., 1996
; Lechleider et al.,
1996
; Macias-Silva et al., 1996
; Massagué, 1996
;
Yingling et al., 1996
; Nakao et al., 1997
).
The fate of the TGF
receptor/ligand complex after receptor
transphosphorylation is unclear. Earlier studies were inconclusive and
suggested that TGF
receptors either did not undergo significant down-regulation (Massagué, 1985
; Wakefield et al.,
1987
) or showed an approximate 50% decrease in TGF
surface binding
by 2 h (Frolik et al., 1984
). At first glance it is
difficult to understand why such important basic information would be
lacking in a growth factor/receptor system with such a fundamental role
in growth and development. The reasons for this are probably twofold.
First, quantitative 125I-labeled TGF
binding assays are
extremely difficult due to the high amount of nonspecific binding
usually observed and although cross-linking studies are capable of
identifying which TGF
binding species are present, they are
inadequate for quantitation. Secondly, the natural occurrence of both
TGF
receptor heteromers and homomers would make any analysis
problematic (Chen and Derynck, 1994
; Henis et al., 1994
).
For instance, because type II receptors have been shown to homodimerize
and heterodimerize in the presence and absence of ligand (Henis
et al., 1994
), there may be distinct endocytic responses for
each of the receptor combinations.
In the present study, we wished to determine 1) whether
signaling-competent heteromeric type I/type II TGF
receptors were internalized and down-regulated; 2) the associated mechanism by which
any endocytic event(s) was regulated; and 3) whether a similar response
was observed for signaling-incompetent homomeric type I/type I or type
II/type II TGF
receptors. To address these questions, we have used a
cellular system capable of specifically and independently examining
heteromeric or homomeric TGF
receptor interactions. Stable cell
lines have been previously characterized expressing chimeric TGF
receptors that have the extracellular ligand binding domain
of the granulocyte/macrophage colony-stimulating factor (GM-CSF)
or
receptor fused to the transmembrane and cytoplasmic domain
of the type I or type II TGF
receptor (Anders and Leof, 1996
).
Because high-affinity ligand binding requires dimerization of the
GM-CSF
and
subunits (Hayashida et al., 1990
;
Kitamura et al., 1991
; Shanafelt et al., 1991
),
the endocytic response of defined heteromeric or homomeric TGF
receptor interactions can be examined (Anders and Leof, 1996
; Muramatsu
et al., 1997
).
The data presented in this manuscript show that internalization per se
is not sufficient for cellular signaling because both heteromeric and
homomeric TGF
receptor combinations are internalized. However,
although both resulting receptor complexes are internalized, only
signaling-competent heteromeric type I/type II TGF
receptor complexes undergo ligand-mediated receptor down-regulation.
| |
MATERIALS AND METHODS |
|---|
|
|
|---|
Materials
Recombinant human GM-CSF was a generous gift from DNAX Research
Institute (Palo Alto, CA), and 125I-labeled recombinant
human GM-CSF and epidermal growth factor (EGF) were purchased from
DuPont/NEN (Boston, MA). To document activation of endogenous TGF
receptors, recombinant human TGF
1 or TGF
2 was purchased from
Austral Biologicals (San Ramon, CA) or R & D Systems (Minneapolis, MN).
Cell Culture
Parental AKR-2B cells were maintained in DMEM (Life
Technologies, Gaithersburg, MD) supplemented with 5% fetal bovine
serum (FBS; Summit, Ft. Collins, CO). Chimeric receptor expressing
clones were grown in 5% FBS/DMEM containing 100 µg/ml bioactive
Geneticin (Life Technologies) and 50 µg/ml Hygromycin B (Sigma, St.
Louis, MO). The designation
I
II (i.e., clone A105) represents a
ligand-activated heteromeric receptor interaction consisting of the
extracellular ligand binding domain of the GM-CSF
receptor fused to
the transmembrane and cytoplasmic domain of the type I TGF
receptor
(i.e.,
I), and the extracellular ligand binding domain of the GM-CSF
receptor fused to the transmembrane and cytoplasmic domain of the
type II TGF
receptor (i.e.,
II). A similar designation is used
for homomeric TGF
receptor interactions seen with clones A120 (i.e.,
I
I) and A122 (i.e.,
II
II). For instance,
I
I would
indicate ligand binding to the GM-CSF
and
receptor
extracellular domains resulting in homomerization of type I TGF
receptor transmembrane and cytoplasmic domains and
II
II would
represent homomeric interactions of the type II TGF
receptor (Anders
and Leof, 1996
).
Internalization Assays
Cultures were plated at 1 × 105 cells/well in
six-well dishes (9.6 cm2/well) for 24 h prior to the
experiment in 5% FBS/DMEM. Ligand binding was performed at 4°C in
binding buffer [DMEM containing 200 mM
N-(2-hydroxyethyl)piperazine-N
-(2-ethanesulfonic
acid) (HEPES), pH 7.4, 25 mg/ml bovine serum albumin (BSA)]
supplemented with 100 pM 125I-labeled GM-CSF (119 µCi/µg) in the presence or absence of a 25-fold molar excess of
unlabeled GM-CSF to document specific binding (routinely 70-90% of
total binding). Once equilibrium had been reached (2-4 h), the plates
were washed and placed at 37°C for the indicated times to promote
receptor endocytosis. Percent internalization (i.e., specific cpm in
cell/specific surface cpm) was determined after acid washing (PBS, pH
3.0; two 3-min washes) to remove surface bound ligand and cell lysis in
0.2 M NaOH and 40 µg/ml salmon sperm DNA. EGF internalization was
measured as described for GM-CSF except the binding buffer was 20 mM
HEPES, 0.1% BSA, and DMEM, pH 7.4, and the acid stripping solution was 50 mM acetic acid, 135 mM NaCl, and 2.5 mM KCl.
125I-labeled EGF binding was measured at 150 pM and
specific binding was determined by incubation with a 200-fold excess of
unlabeled EGF.
Down-Regulation Assays
To determine the effect of ligand on receptor down-regulation, cultures were incubated at 37°C with unlabeled GM-CSF (520 pM or 10 ng/ml) for the indicated times. Surface-bound ligand was removed by acid washing (PBS, pH 3.0) and remaining cell surface receptor binding was determined by incubation at 4°C for 2-4 h with 100 pM 125I-labeled GM-CSF. The plates were washed twice with ice-cold binding buffer, containing 75% horse serum (Life Technologies) and specifically bound 125I-labeled GM-CSF was determined. Control studies have shown that acid washing removes 90-95% receptor-bound ligand without affecting subsequent ligand binding (our unpublished results). For recovery from down-regulation, cells were incubated for 4 h with unlabeled GM-CSF (520 pM or 10 ng/ml) at 37°C and acid washed with PBS, pH 3.0. Cells were then returned to 37°C in the appropriate test medium for the indicated times and specific 125I-labeled GM-CSF binding was determined after 2-4 h at 4°C as described above.
Cytosolic Acidification
Cells were plated at 1 × 105 cells/well in six-well dishes containing 5% FBS/DMEM and grown for 24 h at 37°C. The medium was replaced with 1.0 ml of buffer 1 (30 mM NH4Cl, 200 mM HEPES, DMEM, pH 7.2). After a 30-min incubation at 37°C, the cultures were rinsed and incubated in buffer 2 (140 mM KCl, 20 mM HEPES, 2.0 mM CaCl2, 1 mM MgCl2, 1.0 mM amiloride, pH 7.2) at 37°C for an additional 90 min. Cells were then placed at 4°C for 15 min prior to 125I-labeled GM-CSF (100 pM) binding (buffer 2 containing 2.5% BSA) for 2-4 h at 4°C. Ligand internalization was determined as described above. Control cells were treated identically except that NH4Cl was omitted from the first 30-min incubation and amiloride was not present in subsequent incubations.
Potassium Depletion
Potassium depletion of cells was performed essentially as
described by Larkin et al. (1983)
and Sorkin et
al. (1995)
. Cultures initially received a 5-min hypotonic shock
with DMEM/H2O (1:1) at 37°C followed by a 10-min
incubation at 37°C in buffer A (50 mM HEPES, 100 mM NaCl, pH 7.4) and
a 30-min in buffer B (50 mM HEPES, 100 mM NaCl, 1 mM CaCl2,
2.5% BSA, pH 7.4). Cells were then placed at 4°C (in buffer B) for
15 min and replaced with buffer B containing 100 pM
125I-labeled GM-CSF. Binding and internalization were
measured as described above. Control cells were treated as above but
did not undergo initial hypotonic shock, and subsequent incubations in buffers A and B were performed in the presence of 10 mM KCl.
Determination of Bulk Flow Uptake
To ascertain that potassium depletion did not disrupt bulk-phase
endocytosis, we used the method described by Cupers et al. (1994)
, with minor modifications. Potassium depletion was as previously described with horseradish peroxidase (HRP; 2 mg/ml) substituted for
radiolabeled GM-CSF. HRP was dissolved in buffer B with and without
potassium and incubated with the cells on ice for 15 min prior to
warming for various times. Plates were warmed to 37°C and at the
indicated times internalization was stopped by placing the plates on
ice. Cells were then washed as described by Cupers et al.
(1994)
, lysed with 0.4 ml of 0.05% Triton X-100 in 10 mM Tris(hydroxymethyl)aminomethane, pH 7.4, and scraped from the wells.
Endocytosis of HRP was measured by the colorometric assay using
o-dianisidine (Sigma) as a substrate (Marsh et
al., 1987
). Cell lysates (25 µl) were mixed with 0.342 mM
o-dianisidine in 0.5 M KH2PO4, pH
5.0, 0.3% Triton X-100, and 0.006% H2O2, and HRP activity measured at 490 nm in a microplate reader (Molecular Devices, Sunnyvale, CA). Standard curves were used to determine the
mass of HRP internalized and expressed relative to total BCA protein
(Pierce Chemicals, Rockford, IL).
| |
RESULTS |
|---|
|
|
|---|
Internalization of Chimeric Receptor Heteromeric and Homomeric Combinations
The fate of TGF
receptors after ligand-induced association is
unclear. To address these general questions relating TGF
receptor internalization and activation, we have devised a chimeric receptor system capable of distinguishing the contribution of TGF
receptor homomers, either type I/type I or type II/type II, from heteromeric type I/type II TGF
receptors (Anders and Leof, 1996
; Muramatsu et al., 1997
). To study the fate of ligand-bound receptors,
internalization assays were performed on the two heteromer clones (A105
and A110) and a representative type I (A120) or type II (A122) receptor homomer expressing clone. Equilibrium 125I-labeled GM-CSF
binding was performed at 4°C on each of the clones. The cultures were
shifted to 37°C, and at the indicated times, the internalized and
surface-bound ligand was determined as described in MATERIALS AND
METHODS. As shown in Figure 1, similar
rates (and amount) of internalization were observed for all the
receptor combinations although there was some variation between
individual clones (i.e., A110 showed an higher ratio of internalized to
surface-bound ligand at 120 or 240 min than any of the other clones).
|
The endocytotic rate constant (ke) for each
clone representing the slope of the line when the ratio of internalized
ligand to surface-bound ligand is plotted as a function of time is
shown in Figure 1 (Wiley and Cunningham, 1982
). Although no significant difference was observed for any of the clones, the calculated rates for
the chimeric receptors were 5- to 10-fold slower than that reported for
the EGF receptor (Wiley and Cunningham, 1982
; Waters et al.,
1990
; Rajagopalan et al., 1991
; Chang et al.,
1993
; Sorkin et al., 1996
) and about 3- to 4-fold slower
than the growth hormone receptor or chimeric EGF/Erb B receptors
(Baulida et al., 1996
; Harding et al., 1996
).
Although the significance of these relatively slow receptor kinetics is
presently unknown, it may provide a possible explanation to why classic
signaling pathways have not been consistently documented as downstream
mediators of TGF
receptor activation.
Clathrin-mediated Internalization of Heteromeric and Homomeric
GM-CSF/TGF
Receptors
Growth factor receptors are frequently internalized through
structures referred to as clathrin-coated pits (Schmid, 1992
). Because
signaling-incompetent homomeric receptors were internalized to a
similar extent as signaling-competent heteromeric receptors (Figure 1),
we wished to first determine the mechanism of internalization and
second to determine whether it differed between these receptor groups.
To examine this question, clathrin-dependent internalization was
prevented by K+ depletion (prevents clathrin lattice
formation; Larkin et al., 1983
; Sorkin et al.,
1995
) or cytoplasmic acidification (prevents the pinching off of
clathrin buds; Fire et al., 1995
). As shown in Figure
2, A and B, 125I-labeled
GM-CSF internalization was inhibited 80-90% by either K+
depletion or cytoplasmic acidification of the heteromeric receptor expressing A105 clone. Moreover, there was no effect of amiloride alone
(i.e., in the absense of NH4Cl and subsequently no
acidification) on ligand internalization (our unpublished results). The
Figure 2B inset represents a positive control performed in parallel
showing comparable clathrin dependence to EGF internalization (Sorkin and Water, 1993
). To determine whether homomeric type I/type I or type
II/type II receptors internalized ligand in an analogous manner, the
experiments shown in Figure 2, C and D, were performed. Similar to that
observed for heteromeric receptor internalization (Figure 2, A and B),
homomeric receptors were unable to internalize radiolabeled ligand in
the absence of K+, yet internalization occurred once
K+ was restored to the cultures.
|
The preceding data support the hypothesis that the primary mechanism
for chimeric TGF
receptor internalization is clathrin-dependent. However, although the pharmacologic approaches in Figure 2 are commonly
used to indicate clathrin dependence, they are not specific. To
determine whether our treatments were resulting in a generalized disruption of the endocytic machinery, we examined the effect of
K+ depletion on the clathrin-independent uptake of the
fluid-phase marker HRP (Cupers et al., 1994
; Damke et
al., 1994
). As shown in Figure 3,
similar rates and amounts of HRP were internalized over the first 10 min in the presence or absence of potassium. In agreement with the
results of Cupers et al. (1994)
, HRP accumulation decreased
approximately 30.3% in treated cells after a 10-min internalization,
presumably a reflection of an intermediate compartment regurgitating
its content. Because the intracellular uptake of the fluid-phase tracer
HRP was not impaired by K+ depletion, the results of Figure
2 are most consistent with a clathrin-dependent process being the
primary mechanism through which chimeric TGF
receptors are
internalized. Thus, although homomeric receptor combinations are unable
to signal (Anders and Leof, 1996
; Luo and Lodish, 1996
; Muramatsu
et al., 1997
), they undergo clathrin (and ligand)-dependent
internalization with kinetics similar to signaling-competent
heteromeric TGF
receptors.
|
Differential Down-Regulation of Chimeric Heteromeric and Homomeric Receptors
The finding that homomeric TGF
receptor interactions were
internalized similarly to heteromeric TGF
receptors (Figures 1 and
2) indicated that internalization, per se, was in itself not sufficient
to transmit a biological response. Although internalization is usually
followed by a decrease in ability to bind ligand due to receptor
down-regulation, we observed differing results when down-regulation
assays were performed on the heteromeric and homomeric receptor
expressing clones (Figure 4). Cells were
treated with 10 ng/ml unlabeled GM-CSF for 4 h at 37°C and acid
stripped to remove any remaining receptor-bound ligand, and
125I-labeled GM-CSF surface binding was measured at 4°C.
As shown in Figure 4, heteromeric receptor expressing clones A105 and
A110 showed only 20-30% binding, relative to time zero, after a 2- to
4-h treatment with 10 ng/ml GM-CSF (70-80% receptor down-regulation). In contrast, homomeric clones A120 and A122 showed no decrease in
surface binding throughout the 4-h GM-CSF treatment. In fact, clone
A120 showed an increase in surface binding by 4 h, the
significance of which is presently unknown. These results (Figures 1
and 2, and see Figure 4) suggest that heteromeric and homomeric TGF
receptors undergo distinct trafficking behavior after ligand-induced oligomerization.
|
Dose and Temperature Dependence of Ligand-induced Down-Regulation
Receptor down-regulation occurs through an endocytic mechanism
dependent upon the dose of the ligand and the temperature of incubation. To determine whether down-regulation of the chimeric TGF
receptor showed a similar dependence, down-regulation assays were
performed with various GM-CSF concentrations and differing temperatures. Figure 5A shows that
receptor down-regulation of heteromeric clone A105 occurs in a
dose-dependent manner with a half-maximal response seen at 0.2-0.4
ng/ml (10.4-20.8 pM) GM-CSF. This concentration of GM-CSF correlates
well with the apparent chimeric receptor Kd of
7.8 ± 13.4 pM (our unpublished results) for the A105 clone and is
similar to the GM-CSF dose dependence shown previously for induction of
plasminogen activator inhibitor 1 protein (Anders and Leof, 1996
).
|
Earlier studies have shown that endocytosis through clathrin-coated
pits is highly dependent upon the temperature of incubation (Pearse and
Robinson, 1990
; Schmid, 1992
). Although Figure 2 indicated a clathrin
requirement for chimeric receptor internalization, down-regulation
assays were performed with GM-CSF treatment at 4°C, 25°C, or
37°C. In agreement with the results of Figure 4, 37°C GM-CSF
treatment resulted in a 70% decrease in cell surface receptor binding
by 2 h (Figure 5B). However, treatment with GM-CSF at 4°C or
25°C caused no appreciable down-regulation of the chimeric receptors.
These results (Figures 2, 4, and 5) are consistent with the hypothesis
that the endocytosis of heteromeric signaling competent TGF
receptors is dependent upon 1) functional clathrin lattice formation,
2) the dose of ligand, and 3) the temperature of incubation.
Recovery from Down-Regulation
Receptor down-regulation is usually considered one mechanism by which the cellular response to bioactive molecules is dampened. It follows, however, that the decrease in cell surface receptor expression must be replenished to respond to subsequent signals. Because the clones (A105 and A110) expressing heteromeric combinations of chimeric receptors underwent a ligand-dependent decrease in surface receptor binding, we wished to determine the cellular requirement(s) for returning receptor binding to the prestimulatory level. To address that question, cells were treated with GM-CSF to down-regulate the receptors and allowed to recover in normal growth medium (5% FBS), growth medium supplemented with actinomycin D, or growth medium containing cycloheximide (Figure 6). At the indicated recovery times, cell surface binding was measured with radiolabeled GM-CSF. As shown in Figure 6, receptor binding attained the initial control level 6-8 h after addition of growth medium. Although the recovery in binding was dependent upon new protein synthesis, as cycloheximide treatment blocked recovery, control binding levels were attained in the presence of the mRNA synthesis inhibitor actinomycin D.
|
| |
DISCUSSION |
|---|
|
|
|---|
Understanding the events after TGF
receptor activation have
been limited by poor TGF
binding assays and the finding that homomeric and heteromeric TGF
receptor interactions occur on the
cell surface (Henis et al., 1994
). To circumvent these
problems, we have generated a chimeric receptor system that
qualitatively and quantitatively recapitulates both short-term gene
expression and long-term biological responses dependent upon TGF
signaling events (Anders and Leof, 1996
; Muramatsu et al.,
1997
). Isolation of clones expressing homomeric type I/type I or type
II/type II and heteromeric type I/type II TGF
receptor combinations
has allowed us to initiate studies examining the endocytic response of
distinct receptor complexes.
It was first determined that heteromeric and homomeric
receptor/ligand-induced complexes were internalized (Figure 1).
Although there is some variation in the degree of internalization, the overall rate of internalization is statistically similar between all
the clones tested (Figure 1 and our unpublished results). It is of
interest that the chimeric TGF
receptors internalize ligand at a
slower rate from that observed in tyrosine kinase receptors, such as
the EGF receptor. For instance, the endocytotic rate constant
(ke), defined as the probability of an occupied receptor being internalized in 1 min at 37°C, is 5- to 10-fold slower
for the chimeric TGF
receptors than the EGF receptor. Although one
can never disprove the possibility that these relatively slow kinetics
are a reflection of the chimeric receptor system, the endocytic
constants reported from other chimeric systems are similar to those
seen in the native receptor (Rajagopalan et al., 1995
; Tseng
et al., 1995
). Moreover, the elements regulating receptor endocytosis are commonly found in the cytoplasmic domains of most receptors (Trowbridge et al., 1993
) and GM-CSF receptors
have been reported to not internalize in mouse fibroblasts (Watanabe et al., 1993
). Because our previous findings showed that the
chimeric receptors quantitatively and qualitatively reconstituted
TGF
receptor signaling, this further suggests that the observed
internalization rates reflect the endogenous receptor system. One
possibility might be that because the endogenous (and the chimeric)
TGF
receptor requires the formation of an heteromeric complex
between differing receptor types (i.e., a dimeric and/or tetrameric
complex), analogies to one-component systems (i.e., EGF receptor) may
be inappropriate.
Although our results and data from other laboratories document
internalization of ligand bound to chimeric and native TGF
receptors
(Massagué and Like, 1985
; O'Grady et al., 1991
;
Rakowicz-Szulczynska et al., 1994
; Dickson et
al., 1995
; Muramatsu et al., 1997
), a recent
publication by Koli and Arteaga (1997) reports minimal internalization
of 125I-labeled TGF
at 37°C. It is unclear why these
investigators obtained such different results. One explanation might be
that because their internalization assays were not done after
steady-state binding, the dissociation rate at 37°C would mask the
apparent slow (relative to the EGF receptor) rate of internalization.
Furthermore, their data appeared to show increasing ligand
internalization at the end of the assay.
Although receptor-mediated pinocytosis has most commonly been
reported to occur through clathrin-coated vesicles, recent reports have
suggested other mechanisms such as caveolae, macropinocytosis, or
noncoated vesicles for various growth factor receptors (Lamaze and
Schmid, 1995
). Because there was essentially no information concerning
the mechanism(s) through which TGF
receptors were internalized, we
wished to determine whether the chimeric receptors were endocytosed
through a clathrin-dependent or -independent process. Moreover, because
this system has the distinct advantage of separately examining the
endocytic response of TGF
receptor homomers and heteromers, we could
also determine whether the comparable endocytic rate seen for both
receptor families reflected similar or distinct mechanisms. As shown in
Figure 2, the internalization of both heteromeric and homomeric
receptor complexes was inhibited by K+ depletion or
cytosolic acidification. Although both treatments are known to disrupt
clathrin-dependent processes, they are not entirely specific. To
document that the inhibitory effect seen in Figure 2 was not reflecting
a generalized disruption of the endocytic machinery, we also
determined whether the clathrin-independent uptake of the fluid-phase
tracer HRP was affected by K+ depletion (Figure 3). In
agreement with previous studies (Cupers et al., 1994
), we
found no effect of K+ depletion on the initial rate of HRP
internalization. Whether the effect seen at later times reflects
regurgitation from an early endosomal compartment as shown by Cupers
et al. (1994)
is unknown. An additional mechanism by which
receptors are internalized is through the process of macropinocytosis
(West et al., 1989
; Hewlett et al., 1994
; Lamaze
and Schmid, 1995
). However, macropinocytosis is inhibited by amiloride
in the absence of cytosolic acidification (West et al.,
1989
), and we found no effect of amiloride alone (i.e., no
NH4Cl and subsequently no cytosolic acidification) on chimeric receptor internalization (our unpublished results). Thus, although morphologic studies such as electron microscopic
colocalization will be needed to definitively prove a
clathrin-dependent mechanism, the data strongly support that
conclusion. Whether internalization also requires the activity of a
GTPase such as dynamin for the pinching off of the endocytic bud
(Urrutia et al., 1997
) or the association with proteins
composing the AP-2 complex (Pearse and Robinson, 1990
; Nesterov
et al., 1995
; Sorkin et al., 1995
, 1996
) is
currently under investigation.
Internalization of bound ligand is usually followed by a decrease in
cell surface receptors referred to as down-regulation. There have been
conflicting reports whether TGF
receptors undergo ligand-mediated
down-regulation. Initial studies suggested that a large intracellular
pool of recycling receptors replenished cell surface binding after
internalization (Massagué, 1985
; Massagué and Kelly, 1986
;
Sathre et al., 1991
). However, these data were based upon
the results of ligand binding to both endogenous heteromeric and
homomeric TGF
receptors and/or the earlier consideration that the
type III receptor (beta glycan) was the primary signaling receptor for
TGF
. More recent studies (O'Grady et al., 1991
; Zhao and
Buick, 1995
; Muramatsu et al., 1997
) and the results of the
present investigation show that type I and type II TGF
receptors are
down-regulated and that distinct endocytic effects are observed for
TGF
receptor heteromers and homomers. For instance, although
heteromeric type I/type II TGF
receptor interactions result in both
internalization and receptor down-regulation, homomeric type I/type I
or type II/type II TGF
receptors are internalized but not
down-regulated (Figures 1 and 4). One possible mechanism to account for
this difference might be that the ability to down-regulate is directly
tied to the signaling capability of the receptor combination. Because
homomeric receptor interactions are signaling incompetent (Anders and
Leof, 1996
; Luo and Lodish, 1996
; Muramatsu et al., 1997
),
only signaling-competent heteromeric receptors would be down-regulated.
However, this possibility is unlikely because signaling-incompetent
heteromeric receptors containing a kinase dead type I TGF
receptor
are down-regulated to the same extent and with similar kinetics as
functional heteromers (our unpublished results). A similar result was
reported by Opresko and Wiley (1990)
showing that kinase-negative EGF
receptors would internalize ligand but not down-regulate when expressed
in Xenopus oocytes. Another explanation might be that
homomeric and heteromeric receptor/ligand complexes are processed
through distinct endocytic pathways. This would be consistent with
ligand binding assays in which homomeric receptors were internalized
but not down-regulated. Moreover, it might also account for the initial
confusion in the endocytic fate of TGF
receptors because earlier
binding studies would have generated results based upon the overall
endocytic response of both heteromeric and homomeric TGF
receptor
interactions. For instance, because type II TGF
receptor homomers
occur in the presence or absence of ligand (Henis et al.,
1994
), the down-regulation of endogenous heteromeric TGF
receptors
might be masked by the binding of ligand to homomeric type II receptors
still present on the cell surface. In addition, the previous
determination that TGF
receptors are recycled (Frolik et
al., 1984
; Massagué and Kelly, 1986
; Sathre et
al., 1991
) could also be similarly accounted for by our finding
that TGF
receptor homomers are internalized but not down-regulated.
Because these earlier TGF
binding studies would not differentiate
the response of heteromeric from homomeric TGF
receptor
interactions, the "recycled" receptor component might reflect
ligand binding to type II TGF
homomers that have trafficked back to
the plasma membrane after internalization. We are not hampered by these
considerations because the chimeric receptor system is capable of
distinguishing the cellular response of defined heteromeric and
homomeric receptor populations.
Additional studies examined both the temperature requirement for
down-regulation and the synthetic requirements for replenishing ligand
binding after down-regulation (Figures 5B and 6). The lack of receptor
down-regulation at 25°C was somewhat surprising and differs from that
routinely observed in other growth factor receptors, such as EGF or
insulin. However, similar findings (i.e., down-regulation at 37°C but
not at room temperature or 15°C) have been reported for both the
human chorionic gonadotropin receptor (Rebois and Fishman, 1984
) and
the T cell receptor
-chain (Makida et al., 1996
). Whether
this response is unique to the chimeric receptors or reflects an
unusual property of TGF
receptors is presently unknown and under
investigation. Nonetheless, it suggests a step other than
clathrin-coated pit assembly and budding being rate limiting for this
class of receptors.
The present data suggest several new ideas regarding TGF
receptor
interactions including 1) proposing internalization rates for
heteromeric and homomeric TGF
receptor complexes, 2) providing evidence that the mechanism of receptor endocytosis is
clathrin-dependent, 3) demonstrating that only heteromeric type I/type
II TGF
receptor combinations down-regulate in a dose- and
temperature-dependent manner, and 4) showing that the subsequent
recovery from down-regulation is dependent upon new protein synthesis
but can occur in the presence of actinomycin D, indicating that a large
intracellular pool of receptors may not be present. Although our
results using a defined chimeric receptor system agree and/or extend
many earlier reports analyzing endogenous TGF
receptors, it is
readily apparent that additional studies will be required to
appropriately characterize this extremely complex receptor system.
| |
ACKNOWLEDGMENTS |
|---|
We thank M. Edens for outstanding technical assistance. This work was supported by grants GM-54200 from the National Institutes of Health and the Levy Foundation.
| |
FOOTNOTES |
|---|
* Corresponding author: Guggenheim 6, Mayo Clinic, Rochester, MN 55905.
| |
REFERENCES |
|---|
|
|
|---|
(TGF-
) receptors define a model system for investigating the role of homomeric and heteromeric receptors in TGF-
signaling.
J. Biol. Chem.
271, 21758-21766
in normal rat kidney fibroblasts.
J. Biol. Chem.
259, 10995-11000
type I and type II receptors.
J. Biol. Chem.
272, 6423-6427
signalling pathways.
Nature
383, 832-836[Medline].
signal transduction by human bsp-1.
J. Biol. Chem.
271, 17617-17620
receptors: homodimerization of the cytoplasmic domain of the type I TGF
receptor and heterodimerization iwth the type II receptor are both required for intracellular signal transduction.
EMBO J.
15, 4485-4496[Medline].
receptor and its phosphorylation is required for nuclear accumulation and signaling.
Cell
87, 1215-1224[Medline].
transforming growth factor receptors in cells chronically exposed to the ligand.
Cancer Cells
3, 73-78.
signaling: receptors, transducers, and mad proteins.
Cell
85, 947-950[Medline].
receptors and TGF-
binding proteoglycans: recent progress in identifying their functional properties.
Ann. N.Y. Acad. Sci.
593, 59-72[Medline].
and its receptor in BALB/c 3T3 fibroblasts.
J. Cell. Physiol.
128, 216-222[Medline].
transforming growth factor.
J. Biol. Chem.
260, 2636-2645
.
Mol. Biol. Cell
8, 469-480[Abstract].
signaling pathway.
J. Biol. Chem.
272, 2896-2900
1 by human hepatoma cells: evidence for receptor recycling.
Hepatology
14, 287-295[Medline].
.
J. Cell Biol.
105, 965-975
and are implicated in control of cell growth.
Proc. Natl. Acad. Sci. USA
93, 8940-8944This article has been cited by other articles:
![]() |
Y. Zhang, X. Li, J. Qi, J. Wang, X. Liu, H. Zhang, S.-C. Lin, and A. Meng Rock2 controls TGF{beta} signaling and inhibits mesoderm induction in zebrafish embryos J. Cell Sci., July 1, 2009; 122(13): 2197 - 2207. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. C. Finger, N. Y. Lee, H.-j. You, and G. C. Blobe Endocytosis of the Type III Transforming Growth Factor-{beta} (TGF-{beta}) Receptor through the Clathrin-independent/Lipid Raft Pathway Regulates TGF-{beta} Signaling and Receptor Down-regulation J. Biol. Chem., December 12, 2008; 283(50): 34808 - 34818. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. J. Murphy, K. E. Shapira, Y. I. Henis, and E. B. Leof A Unique Element in the Cytoplasmic Tail of the Type II Transforming Growth Factor-beta Receptor Controls Basolateral Delivery Mol. Biol. Cell, October 1, 2007; 18(10): 3788 - 3799. [Abstract] [Full Text] [PDF] |
||||
![]() |
Q. Jin, W. Ding, and K. M. Mulder Requirement for the Dynein Light Chain km23-1 in a Smad2-dependent Transforming Growth Factor-beta Signaling Pathway J. Biol. Chem., June 29, 2007; 282(26): 19122 - 19132. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. A. Smith, F. Stauber, C. Waters, S. E. Alway, and W. T. Stauber Transforming growth factor-beta following skeletal muscle strain injury in rats J Appl Physiol, February 1, 2007; 102(2): 755 - 761. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Asano, H. Ihn, K. Yamane, M. Jinnin, and K. Tamaki Increased Expression of Integrin {alpha}v{beta}5 Induces the Myofibroblastic Differentiation of Dermal Fibroblasts Am. J. Pathol., February 1, 2006; 168(2): 499 - 510. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Boxall, S. T. Holgate, and D. E. Davies The contribution of transforming growth factor-{beta} and epidermal growth factor signalling to airway remodelling in chronic asthma Eur. Respir. J., January 1, 2006; 27(1): 208 - 229. [Abstract] [Full Text] [PDF] |
||||
![]() |
S Baraldo, E Bazzan, G Turato, F Calabrese, B Beghe, A Papi, P Maestrelli, L M Fabbri, R Zuin, and M Saetta Decreased expression of TGF-{beta} type II receptor in bronchial glands of smokers with COPD Thorax, December 1, 2005; 60(12): 998 - 1002. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Mitchell, A. Choudhury, R. E. Pagano, and E. B. Leof Ligand-dependent and -independent Transforming Growth Factor-{beta} Receptor Recycling Regulated by Clathrin-mediated Endocytosis and Rab11 Mol. Biol. Cell, September 1, 2004; 15(9): 4166 - 4178. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. J. Murphy, J. J. E. Dore, M. Edens, R. J. Coffey, J. A. Barnard, H. Mitchell, M. Wilkes, and E. B. Leof Differential Trafficking of Transforming Growth Factor-{beta} Receptors and Ligand in Polarized Epithelial Cells Mol. Biol. Cell, June 1, 2004; 15(6): 2853 - 2862. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. S. Siddiqui, Z. K. Siddiqui, and A. B. Malik Albumin endocytosis in endothelial cells induces TGF-{beta} receptor II signaling Am J Physiol Lung Cell Mol Physiol, May 1, 2004; 286(5): L1016 - L1026. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Janssens, P. ten Dijke, S. H. Ralston, C. Bergmann, and W. Van Hul Transforming Growth Factor-beta 1 Mutations in Camurati-Engelmann Disease Lead to Increased Signaling by Altering either Activation or Secretion of the Mutant Protein J. Biol. Chem., February 21, 2003; 278(9): 7718 - 7724. [Abstract] [Full Text] [PDF] |
||||
![]() |
Q. Tang, C. M. Staub, G. Gao, Q. Jin, Z. Wang, W. Ding, R. E. Aurigemma, and K. M. Mulder A Novel Transforming Growth Factor-beta Receptor-interacting Protein That Is Also a Light Chain of the Motor Protein Dynein Mol. Biol. Cell, December 1, 2002; 13(12): 4484 - 4496. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Yao, M. Ehrlich, Y. I. Henis, and E. B. Leof Transforming Growth Factor-beta Receptors Interact with AP2 by Direct Binding to beta 2 Subunit Mol. Biol. Cell, November 1, 2002; 13(11): 4001 - 4012. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. Lu, J. T. Murray, W. Luo, H. Li, X. Wu, H. Xu, J. M. Backer, and Y.-G. Chen Transforming Growth Factor beta Activates Smad2 in the Absence of Receptor Endocytosis J. Biol. Chem., August 9, 2002; 277(33): 29363 - 29368. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. G. Penheiter, H. Mitchell, N. Garamszegi, M. Edens, J. J. E. Dore Jr., and E. B. Leof Internalization-Dependent and -Independent Requirements for Transforming Growth Factor {beta} Receptor Signaling via the Smad Pathway Mol. Cell. Biol., July 1, 2002; 22(13): 4750 - 4759. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. S. Seto, H. J. Bellen, and T. E. Lloyd When cell biology meets development: endocytic regulation of signaling pathways Genes & Dev., June 1, 2002; 16(11): 1314 - 1336. [Full Text] [PDF] |
||||
![]() |
T. Matsuzaki, S. Hanai, H. Kishi, Z. Liu, Y. Bao, A. Kikuchi, K. Tsuchida, and H. Sugino Regulation of Endocytosis of Activin Type II Receptors by a Novel PDZ Protein through Ral/Ral-binding Protein 1-dependent Pathway J. Biol. Chem., May 17, 2002; 277(21): 19008 - 19018. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Fanayan, S. M. Firth, and R. C. Baxter Signaling through the Smad Pathway by Insulin-like Growth Factor-binding Protein-3 in Breast Cancer Cells. RELATIONSHIP TO TRANSFORMING GROWTH FACTOR-beta 1 SIGNALING J. Biol. Chem., February 22, 2002; 277(9): 7255 - 7261. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Garamszegi, J. J. E. Dore Jr., S. G. Penheiter, M. Edens, D. Yao, and E. B. Leof Transforming Growth Factor beta Receptor Signaling and Endocytosis Are Linked through a COOH Terminal Activation Motif in the Type I Receptor Mol. Biol. Cell, September 1, 2001; 12(9): 2881 - 2893. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. J.E. Doré Jr., D. Yao, M. Edens, N. Garamszegi, E. L. Sholl, and E. B. Leof Mechanisms of Transforming Growth Factor-{beta} Receptor Endocytosis and Intracellular Sorting Differ between Fibroblasts and Epithelial Cells Mol. Biol. Cell, March 1, 2001; 12(3): 675 - 684. [Abstract] [Full Text] |
||||
![]() |
M Ehrlich, A Shmuely, and Y. Henis A single internalization signal from the di-leucine family is critical for constitutive endocytosis of the type II TGF-(&bgr;) receptor J. Cell Sci., January 5, 2001; 114(9): 1777 - 1786. [Abstract] [PDF] |
||||
![]() |
D. Yao, J. J. E. Dore Jr., and E. B. Leof FKBP12 Is a Negative Regulator of Transforming Growth Factor-beta Receptor Internalization J. Biol. Chem., April 21, 2000; 275(17): 13149 - 13154. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. PIEK, C.-H. HELDIN, and P. TEN DIJKE Specificity, diversity, and regulation in TGF-{beta} superfamily signaling FASEB J, December 1, 1999; 13(15): 2105 - 2124. [Abstract] [Full Text] |
||||
![]() |
Z. Wang, L. Zhang, T. K. Yeung, and X. Chen Endocytosis Deficiency of Epidermal Growth Factor (EGF) Receptor-ErbB2 Heterodimers in Response to EGF Stimulation Mol. Biol. Cell, May 1, 1999; 10(5): 1621 - 1636. [Abstract] [Full Text] |
||||
![]() |
V. Hurst IV, P. L. Goldberg, F. L. Minnear, R. L. Heimark, and P. A. Vincent Rearrangement of adherens junctions by transforming growth factor-beta 1: role of contraction Am J Physiol Lung Cell Mol Physiol, April 1, 1999; 276(4): L582 - L595. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. J. E. Dore Jr., M. Edens, N. Garamszegi, and E. B. Leof Heteromeric and Homomeric Transforming Growth Factor-beta Receptors Show Distinct Signaling and Endocytic Responses in Epithelial Cells J. Biol. Chem., November 27, 1998; 273(48): 31770 - 31777. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. A. Anders, J. J. E. Dore Jr., S. L. Arline, N. Garamszegi, and E. B. Leof Differential Requirement for Type I and Type II Transforming Growth Factor beta Receptor Kinase Activity in Ligand-mediated Receptor Endocytosis J. Biol. Chem., September 4, 1998; 273(36): 23118 - 23125. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. C. Zwaagstra, M. El-Alfy, and M. D. O'Connor-McCourt Transforming Growth Factor (TGF)-beta 1 Internalization. MODULATION BY LIGAND INTERACTION WITH TGF-beta RECEPTORS TYPES I AND II AND A MECHANISM THAT IS DISTINCT FROM CLATHRIN-MEDIATED ENDOCYTOSIS J. Biol. Chem., July 13, 2001; 276(29): 27237 - 27245. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||